GlaxoSmithKline, Pfizer deal

GlaxoSmithKline will sell quadrivalent meningitis vaccines Nimenrix and Mencevax to Pfizer for EUR115 million ($130.2 million) to address competition concerns raised by the European Commission. Earlier this year, GSK acquired meningitis vaccines Menveo and Bexsero through an asset swap with Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland). The EC cleared the asset swap after GSK agreed to sell Nimenrix and Mencevax. Combined global sales of Nimenrix and Mencevax were L34 million ($53.9 million) in 2014. GSK sells the vaccines against Neisseria meningitidis A, C, W and Y outside the U.S. ...